Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBY trial of dostarlimab with carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer
NL-OMON52421Phase 3Recruiting
- Sponsor
- TESARO, Inc.
- Start
- Jul 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dostarlimab, niraparib, carboplatin and paclitaxel in endometrial cancer (EC) and uterine cancer (4 arms), sponsored by TESARO, Inc. Primary endpoints: Progression-free survival and Overall survival. Started Jul 2020; status: recruiting.
02
Drugs
dostarlimabniraparibcarboplatinpaclitaxel
03
Conditions
endometrial cancer (EC)uterine cancer
Beyond the preview
Go deeper on NL-OMON52421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52421.